SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending with community members actively discussing potential integrations with Solana ($SOL) and USDC. Some users express bullish sentiment, while others are cautioning about potential risks. The conversation includes community-specific language such as WAGMI (We Are All Going to Make It).

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending amid discussions surrounding US-China trade relations and a recent meeting between leaders, with community members debating potential impacts on tariffs and rare earth metal flows. Optimism around potential deals and restarts in soybean trade is contrasted by concerns over Nvidia chip restrictions and the overall market's reliance on a few key stocks. Some traders express caution, pointing to volatility and hedging activity as signs of limited confidence in the ongoing rally.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is buzzing as PayPal's PYUSD stablecoin supply on SOL surpasses $1B, signaling significant real-world adoption and highlighting the blockchain's speed and low fees. The community is anticipating further adoption from other fintech giants, with Western Union mentioned as a potential candidate. Despite some market volatility, bullish sentiment persists as $SOL shows potential for growth.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending due to mixed reactions to earnings, driven by a significant one-time tax charge impacting EPS despite revenue beats. Community discussions revolve around the impact of increased capital expenditures and AI investments on future profitability. Traders are assessing whether the dip represents a buying opportunity or signals deeper concerns about Meta's spending strategy.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVDA is trending as investors digest news around potential chip sales to China following discussions between Trump and Xi, with community sentiment fluctuating based on the perceived outcomes of these talks. Discussions also revolve around Nvidia's high valuation and potential impact of increased capital expenditure from major tech companies. The stock's performance is closely tied to broader AI sector trends and regulatory developments.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

$WAGMI is trending as community members express strong conviction and long-term bullish sentiment, especially alongside $BROKE and $SOL. The community emphasizes collective conviction, aiming for substantial gains and highlighting the coin's resilience.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as traders digest the potential implications of President Trump's meeting with Xi Jinping, particularly regarding tariffs, trade, and technology restrictions, with discussion centering around whether a deal was truly struck or if underlying tensions persist. Community sentiment appears mixed, with some expressing skepticism about any lasting agreements, while others anticipate a positive impact on the market. Broader concerns around liquidity, economic data, and the influence of mega-cap tech companies are also fueling the conversation.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir ($PLTR) is trending as the stock flirts with all-time highs, sparking discussions about a potential stock split and future growth prospects. The community is weighing the impact of recent partnerships, particularly with Nvidia, and anticipating upcoming earnings. Despite valuation concerns, bullish sentiment prevails, fueled by the company's perceived leadership in AI and strong retail investor base.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle's stock is trending due to a significant post-earnings drop, sparking discussions about reduced guidance and declining customer traffic amid macroeconomic pressures. Community members are debating the company's valuation, food quality, portion sizes, and pricing, with some suggesting it's oversold and ripe for institutional investment while others point to waning popularity. The impact of tariffs and competition from other fast-casual restaurants like CAVA are also being considered.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple ($AAPL) is trending as investors anticipate earnings, with community discussions focusing on the potential for a strong report and future AI initiatives. Recent analyst upgrades and positive comments from President Trump are adding to the bullish sentiment. The stock's high valuation remains a point of debate, with some analysts suggesting it needs a blowout earnings report to justify its current price.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kuehn Law Encourages Investors of Capricor Therapeutics, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Capricor Therapeutics, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Capricor Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, Oct. 28, 2025...

Capricor (CAPR) Surges 5.3%: Is This an Indication of Further Gains?

Capricor (CAPR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Capricor Therapeutics (CAPR) said on Thursday that it expects to submit fresh trial data to the U.S. Food and Drug Administration to get its Deramiocel therapy approved in the treatment of Duchenne muscular dystrophy.The FDA <a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-plunges-after-us-fda-declines-approval-for-muscular-disorder-therapy/ch8cfZ4R5Zn">stated</a> in July that it was unable to approve the application for Deramiocel in its current form as it does not meet the requirement for substantial evidence of effectiveness, and expressed the need for additional clinical data.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/326/capricor-therapeutics-provides-regulatory-update-on">stated</a> on Thursday that it held a meeting with the agency and hopes to submit data from its HOPE-3 late-stage clinical trial as part of its current application. Topline data from the trial, which will serve as the additional study requested by the agency, is expected in the fourth quarter.Shares of the company rose 5% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.“The FDA remains committed to collaborating with the applicant and will exercise further regulatory flexibility by reviewing data from the HOPE-3 trial,” the FDA said in a meeting with the company.“With HOPE-3 completed and data expected later this year, we remain confident in our ability to advance Deramiocel toward potential approval,” CEO Linda Marbán said.The company also stated that it maintains a “strong financial position” to support the advancement of Deramiocel through regulatory review and toward a potential launch for treating Duchenne Muscular Dystrophy (DMD).DMD is a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. The disease affects approximately 15,000 individuals in the United States and primarily impacts boys.CAPR stock is down by about 55% this year and by about 40% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bristol-myers-to-sell-plaque-psoriasis-drug-for-over-80-percent-discount-starting-2026/chDlId9R34B">Bristol Myers To Sell Plaque Psoriasis Drug For Over 80% Discount Starting In 2026</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Capricor Stock Rises Pre-Market Over Fresh Hopes Of Deramiocel Approval In Treating Genetic Disorder

The company announced on Thursday that it held a meeting with the agency and plans to submit data from its HOPE-3 clinical trial as part of its current application.

Equity

The company announced on Thursday that it held a meeting with the agency and plans to submit data from its HOPE-3 clinical trial as part of its current application.


Capricor Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - CAPR

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - CAPR Capricor Therapeutics, Inc. Sued for Securities Law Violations...

Faruqi & Faruqi Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 - CAPR

Faruqi & Faruqi Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 - CAPR Faruqi & Faruqi Reminds Capricor Investors of the Pending...

Quanterix Corporation (QTRX) Reports Q2 Loss, Misses Revenue Estimates

Quanterix (QTRX) delivered earnings and revenue surprises of -14.63% and -12.62%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of Replimune Group Inc. (REPL) were in the retail spotlight on Wednesday after the stock nearly doubled in value.BMO Capital expects the stock to witness a meaningful rally following the exit of Vinay Prasad from the U.S. Food and Drug Administration, according to TheFly. Prasad stepped down as Director of the Center for Biologics Evaluation and Research (CBER) on Tuesday, nearly three months into the job.Meanwhile, shares of Capricor Therapeutics (CAPR) and Sarepta Therapeutics (SRPT) clocked moderate gains.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/REPL">Replimune</a> jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1244/130;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_30_at_12_32_01_PM_png_ac2aea7c7b.webp" alt="REPL's Sentiment Meter and Message Volume as of 12:30 p.m. ET on July 30, 2025 | Source: Stocktwits" width="1244" height="130"><figcaption>REPL's Sentiment Meter and Message Volume as of 12:30 p.m. ET on July 30, 2025 | Source: Stocktwits</figcaption></figure>As per Stocktwits data, retail chatter around Replimune surged over 1500% over the past 24 hours.Prasad was appointed in May to replace Peter Marks, who was removed from CBER after conflicting with Health and Human Services Secretary Robert F. Kennedy Jr. over vaccine policy.BMO Capital analyst Evan Seigerman views the exit of Vinay Prasad as a positive for the biopharma sector. A new director will "likely be more permissive of innovation than what we have seen to date," the analyst told investors in a research note.BMO, however, remains uncertain on whether a new CBER director will reconsider the denial of approval to the company’s lead product candidate, RP1.Earlier this month, Replimune received a letter from the FDA indicating that it is unable to approve the company’s application for RP1 in combination with Nivolumab for the treatment of advanced melanoma.The agency deemed the trials cited by the company as not adequate to substantiate the effectiveness of the drug. The FDA also said the trial cannot be adequately interpreted due to the heterogeneity of the patient population.The company then said it will request a meeting with the FDA as it plans to interact with the agency to find a path for approval. CEO Sushil Patel stated that the company is surprised and disappointed by the decision.Leerink, meanwhile, views the exit of Prasad as a positive for rare disease and genetic medicines, negative for vaccines, and unclear for oncology, as per TheFly. While Prasad restricted the use of COVID-19 vaccines during his tenure, Leerink expects the new chief to be more in alignment with Robert F. Kennedy Jr. and his anti-vaccine stance.Shares of <a href="https://stocktwits.com/symbol/CAPR">Capricor</a> Therapeutics also traded 25% higher on Wednesday. The FDA had earlier refused to approve its lead cell therapy candidate for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-names-former-gm-exec-to-lead-commercial-vehicle-segment/choXEl9R5C4">Ford Names Former GM Executive To Lead Commercial Vehicle Segment: Retail’s Skeptical Ahead Of Q2 Earnings Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

REPL Stock Nearly Doubled In Value Today: What's Going On?

Prasad stepped down as the Director of the Center for Biologics Evaluation and Research (CBER) on Tuesday, nearly three months into the job. 

Replimune, Sarepta, Capricor Stocks Surge: Analyst Says Vinay Prasad’s Exit From FDA Positive For Biopharma Sector

FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks

Capricor slumps 33% as the FDA rejects its BLA for DMD drug, deramiocel, citing lack of effectiveness data and CMC issues.

Capricor Therapeutics (CAPR) on Friday said the U.S. Food and Drug Administration (FDA) has refused to approve its lead cell therapy candidate for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy.<a href="https://stocktwits.com/symbol/CAPR">CAPR shares</a> were trading 39% lower in the pre-market session.The FDA <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/319/capricor-therapeutics-provides-regulatory-update-on">told</a> Capricor in a letter that it is unable to approve its application for Deramiocel in its current form as it does not meet the requirement for substantial evidence of effectiveness and expressed the need for additional clinical data.Capricor said the health regulator also referenced certain outstanding items in the Chemistry, Manufacturing, and Controls (CMC) section of the application.The company said it plans to engage further with the FDA to determine the next appropriate steps.Capricor CEO Linda Marbán expressed surprise at the FDA’s decision, calling it “unexpected.” &nbsp;“We have followed their guidance throughout the process. Prior to the CRL (complete response letter), the review had advanced without major issues, including a successful pre-licensure inspection and completion of the mid-cycle review,” she said.The CEO added that the company plans to submit data from a late-stage trial of 104 patients to provide additional evidence of effectiveness. Results from the study are expected in the third quarter of 2025.“We believe these data, if positive, along with our existing long-term clinical results showing cardiac stabilization, preservation of skeletal muscle function, and a consistent safety profile, could support efforts to resolve the questions raised by the FDA for the treatment of cardiomyopathy associated with DMD,” she said.Duchenne Muscular Dystrophy is a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. The disease affects approximately 15,000 individuals in the United States and primarily impacts boys.Over time, deterioration of the heart muscle leads to cardiomyopathy and heart failure, which is the leading cause of death in DMD.DMD therapies have been under increased scrutiny since last month after the FDA <a href="https://stocktwits.com/news-articles/markets/equity/sarepta-stock-slumps-after-fda-opens-probe-into-patient-death-analyst-sounds-alarm/chmJnVnRREn">announced</a> it is investigating the death of two pediatric patients with Duchenne Muscular Dystrophy (DMD) following treatment with Sarepta Therapeutics’ (SRPT) FDA-approved gene therapy Elevidys.FDA is investigating the risk of acute liver failure with serious outcomes, including hospitalization and death, following Elevidys, and is evaluating the need for further regulatory action, the agency said.On Stocktwits, retail sentiment around Capricor remained unmoved within ‘bearish’ territory over the past 24 hours while message volume rose from ‘low’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:1364/128;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_11_at_8_36_02_AM_png_93fa8a7f51.webp" alt="CAPR's Sentiment Meter and Message Volume as of 8:35 a.m. ET on July 11, 2025 | Source: Stocktwits" width="1364" height="128"><figcaption>CAPR's Sentiment Meter and Message Volume as of 8:35 a.m. ET on July 11, 2025 | Source: Stocktwits</figcaption></figure> CAPR stock is down by 17% this year but up by over 148% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/us-regulator-opens-recall-query-into-nearly-28000-polestar-2-vehicles/ch8c9BwR5Zd">US Regulator Opens Recall Query Into Nearly 28,000 Polestar 2 Vehicles, But Retail’s Buoyant</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Capricor Stock Plunges Pre-Market After US FDA Declines Approval For Muscular Disorder Therapy

The FDA told Capricor in a letter that it is unable to approve its application for Deramiocel in its current form as it does not meet the requirement for substantial evidence of effectiveness and expressed the need for additional clinical data.

Jasper Therapeutics faced a wave of downgrades Monday after disclosing that a compromised drug product lot disrupted results in multiple cohorts of its Phase 1b/2a BEACON study evaluating briquilimab for chronic spontaneous urticaria (CSU), a skin allergy.BMO Capital cut the stock to 'Market Perform' from 'Outperform' and slashed its price target to $4 from $15, citing uncertainty caused by manufacturing issues that made it “challenging to separate the signal from the noise.”Cantor Fitzgerald also downgraded the shares to 'Neutral' from 'Overweight', saying the update “introduced uncertainty for clinical trial execution and development timelines.”&nbsp;The firm said it would wait for clarity on future Phase 2b regimens and timelines before re-engaging.William Blair issued a similar downgrade to 'Market Perform' from 'Outperform', flagging a lack of clarity around funding and concerns over the inactive drug lot, which also led Jasper to halt briquilimab development in asthma.&nbsp;The company confirmed that the affected batch was used in all patients in its ETESIAN asthma study.BTIG reduced its price target to $20 from $64 but maintained a 'Buy' rating, calling briquilimab “safe and active” with “compelling efficacy,” despite the paused asthma trial and delayed Phase 2b CSU start, now expected mid-2026.H.C. Wainwright dropped its target to $20 from $40 and retained a 'Buy' rating, citing the “surprising update” on the affected cohorts.&nbsp;The research firm shifted U.S. launch estimates for CSU and chronic inducible urticaria to 2030 and 2031, respectively, and now models a $5 million capital raise.Jasper said the affected cohorts — 240 mg Q8W and 240 mg loading dose plus 180 mg Q8W — showed little to no clinical response, with 10 of 13 patients dosed from the compromised batch.&nbsp;The company plans to replace the products for those patients and enroll 10–12 more across both cohorts. New data is expected in the fourth quarter.Across other cohorts, briquilimab produced deep and durable disease control.&nbsp;In the 240 mg and 360 mg single-dose groups, 8 of 9 participants achieved a complete response, with strong reductions in UAS7 and tryptase levels.&nbsp;Results from the open-label extension study also showed promising efficacy.Jasper is halting asthma and SCID development and may restructure to cut costs and extend its runway.However, retail sentiment for&nbsp;<a href="https://stocktwits.com/symbol/JSPR">Jasper Therapeutics</a> on Stocktwits was ‘extremely bullish’ amid ‘extremely high’ message volume.One user said Jasper looked oversold and predicted a move above $5, calling the reaction to the update an overreaction to 90% good news.<stembedurl>https://stocktwits.com/trt102967/message/620133879</stembedurl>Another user compared the situation to&nbsp;<a href="https://stocktwits.com/symbol/CAPR/news">Capricor Therapeutics</a> , which dropped last month after reports that&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-slumps-on-report-of-key-fda-exec-removal/chlxVk2RRPt">two key FDA officials</a> overseeing the company’s cell therapy application were placed on administrative leave.<stembedurl>https://stocktwits.com/jlove0303/message/620128019</stembedurl>Jasper Therapeutics’ stock has declined 85.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Jasper Therapeutics (JSPR) is investigating a compromised drug batch in its briquilimab skin allergy trial/ Photo credit: Getty Images

Jasper Therapeutics Gets Hit With Downgrades Over Faulty Batch Of Skin Allergy Drug; Retail Sees ‘Overreaction’

The company flagged that 10 of 13 patients in two dosing cohorts received a compromised batch of briquilimab, leading to muted results.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Will Apple (AAPL) beat quarterly earnings? 
 
*Powered by Polymarket

CAPR
Capricor Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CAPR News

CAPRCapricor Therapeutics Inc